DRT, a world leader in plant chemistry and a company of the Firmenich Group, confirms the initial announcement made in September 2019 to invest in a large-scale, state-of-the-art plant to manufacture hydrogenated rosin and resin derivatives.
In September 2019, DRT laid out a plan to invest in a new production unit for highly hydrogenated rosin. The Company today is pleased to announce that this large-scale, state-of-the-art facility is expected to be completed during the 3rd quarter of 2022. The new plant, of which construction was initially delayed due to the Covid-19 pandemic, will place DRT in a strategic position to address the anticipated growth in key industry segments. It will also further strengthen the Company’s global supply capabilities.
Located in Vielle Saint-Girons, France, the project also includes a hydrogenation pilot plant that has already been commissioned and is now fully operational. The new production unit will allow DRT to supply products with the highest degree of hydrogenation available on the market.
This investment will uniquely position DRT as a global supplier of hydrogenated rosin and resin derivatives, with dual production capabilities in Europe and the U.S. This additional capacity will enable DRT to meet the growing demand for sustainable raw materials in a variety of industry segments.
A world leader in plant chemistry, DRT offers its customers renewable pine-based ingredients for the perfumery and industry sectors. With an annual revenue of €550 million and 1,500 employees worldwide, DRT has established a leading position at the forefront of each of its markets thanks to its unique industrial knowledge and ability to innovate along with a strong customer proximity. DRT is a company of the Firmenich Group, the world’s largest privately-owned perfume and taste company.
For more information, visit www.drt.fr.